MX369742B - Formulación de liberación modificada. - Google Patents
Formulación de liberación modificada.Info
- Publication number
- MX369742B MX369742B MX2015017202A MX2015017202A MX369742B MX 369742 B MX369742 B MX 369742B MX 2015017202 A MX2015017202 A MX 2015017202A MX 2015017202 A MX2015017202 A MX 2015017202A MX 369742 B MX369742 B MX 369742B
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- release formulation
- drug products
- drug
- afq056
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940126534 drug product Drugs 0.000 abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- ZFPZEYHRWGMJCV-ZHALLVOQSA-N mavoglurant Chemical compound C([C@]1(O)CCC[C@@H]2[C@H]1CCN2C(=O)OC)#CC1=CC=CC(C)=C1 ZFPZEYHRWGMJCV-ZHALLVOQSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Son proporcionados productos de fármaco en la forma de formulaciones de liberación modificada que comprenden la sustancia farmacológica ester metílico del ácido (-)-(3aR,4S,7aR)-4-Hidroxi-4m-toliletinil-octahidro-indol-1-carbo xílico (AFQ056), así como procedimientos para preparar tales medicamentos. Los productos farmacéuticos son útiles en el tratamiento de pacientes con la enfermedad de Parkinson y que exhiben discinesia inducida por L-dopa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834104P | 2013-06-12 | 2013-06-12 | |
| PCT/IB2014/062136 WO2014199316A1 (en) | 2013-06-12 | 2014-06-11 | Modified release formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015017202A MX2015017202A (es) | 2016-11-11 |
| MX369742B true MX369742B (es) | 2019-11-20 |
Family
ID=51211272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017202A MX369742B (es) | 2013-06-12 | 2014-06-11 | Formulación de liberación modificada. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160128979A1 (es) |
| EP (1) | EP3007682B1 (es) |
| JP (1) | JP6444996B2 (es) |
| KR (1) | KR102290249B1 (es) |
| CN (2) | CN105263479A (es) |
| AU (1) | AU2014279743B2 (es) |
| BR (1) | BR112015030431B1 (es) |
| CA (1) | CA2911486C (es) |
| CL (1) | CL2015003596A1 (es) |
| EA (1) | EA031395B1 (es) |
| ES (1) | ES2644698T3 (es) |
| HK (1) | HK1216839A1 (es) |
| MA (1) | MA38646B1 (es) |
| MX (1) | MX369742B (es) |
| PE (1) | PE20160183A1 (es) |
| PH (1) | PH12015502556A1 (es) |
| PL (1) | PL3007682T3 (es) |
| PT (1) | PT3007682T (es) |
| SG (1) | SG11201509178TA (es) |
| TN (1) | TN2015000498A1 (es) |
| WO (1) | WO2014199316A1 (es) |
| ZA (1) | ZA201508228B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
| EP4119539A1 (en) | 2015-09-23 | 2023-01-18 | XWPharma Ltd. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
| WO2019025931A1 (en) * | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE |
| US12201612B2 (en) | 2017-07-31 | 2025-01-21 | Novartis Ag | Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use |
| CN113301894A (zh) | 2019-01-29 | 2021-08-24 | 诺华股份有限公司 | mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途 |
| CN115942979A (zh) * | 2020-07-17 | 2023-04-07 | 诺华股份有限公司 | 在减少阿片类物质使用的治疗中使用的mglur5拮抗剂玛沃谷兰 |
| JP2023552833A (ja) | 2020-12-11 | 2023-12-19 | ノバルティス アーゲー | アンフェタミン中毒の治療のためのｍＧｌｕＲ５拮抗薬の使用 |
| EP4259127A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Use of mglur5 antagonists for treating gambling disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| US20060216347A1 (en) * | 2003-08-25 | 2006-09-28 | Federico Stroppolo | Tablet punches and methods for tableting |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| US20080085305A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone |
| CA2930487A1 (en) | 2007-01-16 | 2008-07-24 | Egalet Ltd. | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| AU2009307825A1 (en) * | 2008-10-22 | 2010-04-29 | Rick FRIEDMAN | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| WO2012139876A1 (en) * | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
-
2014
- 2014-06-11 PE PE2015002586A patent/PE20160183A1/es not_active Application Discontinuation
- 2014-06-11 US US14/897,439 patent/US20160128979A1/en not_active Abandoned
- 2014-06-11 EP EP14741382.7A patent/EP3007682B1/en active Active
- 2014-06-11 WO PCT/IB2014/062136 patent/WO2014199316A1/en not_active Ceased
- 2014-06-11 CN CN201480031900.0A patent/CN105263479A/zh active Pending
- 2014-06-11 AU AU2014279743A patent/AU2014279743B2/en active Active
- 2014-06-11 MX MX2015017202A patent/MX369742B/es active IP Right Grant
- 2014-06-11 PT PT147413827T patent/PT3007682T/pt unknown
- 2014-06-11 CA CA2911486A patent/CA2911486C/en active Active
- 2014-06-11 HK HK16104528.5A patent/HK1216839A1/zh unknown
- 2014-06-11 SG SG11201509178TA patent/SG11201509178TA/en unknown
- 2014-06-11 PL PL14741382T patent/PL3007682T3/pl unknown
- 2014-06-11 MA MA38646A patent/MA38646B1/fr unknown
- 2014-06-11 BR BR112015030431-1A patent/BR112015030431B1/pt active IP Right Grant
- 2014-06-11 TN TN2015000498A patent/TN2015000498A1/en unknown
- 2014-06-11 JP JP2016518626A patent/JP6444996B2/ja active Active
- 2014-06-11 ES ES14741382.7T patent/ES2644698T3/es active Active
- 2014-06-11 CN CN202010410902.8A patent/CN111467313A/zh active Pending
- 2014-06-11 EA EA201690005A patent/EA031395B1/ru not_active IP Right Cessation
- 2014-06-11 KR KR1020167000347A patent/KR102290249B1/ko active Active
-
2015
- 2015-11-06 ZA ZA2015/08228A patent/ZA201508228B/en unknown
- 2015-11-10 PH PH12015502556A patent/PH12015502556A1/en unknown
- 2015-12-11 CL CL2015003596A patent/CL2015003596A1/es unknown
-
2020
- 2020-06-10 US US16/898,071 patent/US20210069150A1/en active Pending
-
2023
- 2023-07-20 US US18/355,618 patent/US20230355582A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502556A1 (en) | Modified release formulation | |
| CR20140567A (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
| MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| BR112019024747A2 (pt) | formulações de dose fixa | |
| PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| PH12014502834B1 (en) | Pharmaceutical form for extended release of active substances | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| BR112019005426A2 (pt) | composições de éster de colina de ácido lipoico e métodos para estabilizar em produtos de fármaco farmaceuticamente relevantes | |
| MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
| MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| ES2403549R1 (es) | Co-cristales de agomelatina con formadores de co-cristales | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| EP4364810A3 (en) | Topical formulations and uses thereof | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| WO2013127539A3 (de) | Pharmazeutische formulierung enthaltend flupirtin | |
| WO2013054178A8 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
| WO2013109202A3 (en) | Pharmaceutical compounds comprising cefetamet | |
| UA99891C2 (ru) | Производные метил-3-(3-r-6-r-имидазо[1,2-а]пиридин-2-ил)акрилата и способ их получения | |
| MX2012006282A (es) | Uso de las betaxantinas y sus derivados para preparar un medicamento para el tratamiento de aterosclerosis. | |
| HK1218512A1 (zh) | 雜環化合物和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |